A drug usually used to treat rheumatoidarthritis reduces the risk of people in hospital with severe Covid-19 dying. The benefit was on top of that provided by dexamethasone and tocilizumab, two other anti-inflammatory treatments previously shown to reduce the risk of death in these patients. The University of Oxford-led Recovery trial has been trialling a range of potential coronavirus treatments for patients admitted to hospital for Covid-19 since March 2020. Today’s results not only show that
综合
独立报-英国新闻
2022-03-03 00:00:00.0